493 Shares in ABIOMED, Inc. (ABMD) Purchased by Checchi Capital Advisers LLC

Checchi Capital Advisers LLC bought a new stake in ABIOMED, Inc. (NASDAQ:ABMD) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 493 shares of the medical equipment provider’s stock, valued at approximately $222,000.

Other institutional investors also recently modified their holdings of the company. NEXT Financial Group Inc acquired a new stake in shares of ABIOMED in the third quarter valued at approximately $115,000. Cerebellum GP LLC acquired a new stake in shares of ABIOMED in the second quarter valued at approximately $151,000. TRUE Private Wealth Advisors acquired a new stake in shares of ABIOMED in the third quarter valued at approximately $162,000. OLD Mutual Customised Solutions Proprietary Ltd. acquired a new stake in shares of ABIOMED in the second quarter valued at approximately $164,000. Finally, Rampart Investment Management Company LLC acquired a new stake in shares of ABIOMED in the second quarter valued at approximately $175,000. 86.86% of the stock is owned by institutional investors.

In related news, VP Michael G. Howley sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 25th. The shares were sold at an average price of $432.50, for a total transaction of $4,325,000.00. Following the sale, the vice president now owns 48,954 shares in the company, valued at $21,172,605. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Andrew J. Greenfield sold 4,440 shares of the firm’s stock in a transaction that occurred on Wednesday, August 29th. The stock was sold at an average price of $395.00, for a total transaction of $1,753,800.00. The disclosure for this sale can be found here. 3.50% of the stock is currently owned by company insiders.

ABMD has been the topic of several research reports. Zacks Investment Research lowered shares of ABIOMED from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 3rd. BidaskClub upgraded shares of ABIOMED from a “hold” rating to a “buy” rating in a research report on Wednesday, September 5th. ValuEngine lowered shares of ABIOMED from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 18th. Finally, Morgan Stanley increased their price target on shares of ABIOMED from $370.00 to $396.00 and gave the company an “equal weight” rating in a research report on Thursday, October 11th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. ABIOMED has an average rating of “Buy” and an average price target of $384.38.

Shares of NASDAQ ABMD opened at $331.22 on Wednesday. ABIOMED, Inc. has a 1 year low of $180.12 and a 1 year high of $459.75. The company has a market cap of $14.83 billion, a P/E ratio of 135.19, a PEG ratio of 3.42 and a beta of 0.03.

ABIOMED Company Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Read More: What does EPS mean?

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply